Other: Fed Circuit mandate | Aug 23, 2024 | PAPER | BOARD |
Patent Owner's Notice of Appeal | Mar 12, 2024 | PAPER | PATENT OWNER |
Final Written Decision: original | Jan 9, 2024 | PAPER | BOARD |
Petitioner's Amended Mandatory Notices | Dec 20, 2023 | PAPER | PETITIONER |
Petitioner's Amended Mandatory Notices | Nov 29, 2023 | PAPER | PETITIONER |
Other: Hearing transcript | Nov 27, 2023 | PAPER | BOARD |
Patent Owner's Amended Mandatory Notices | Nov 16, 2023 | PAPER | PATENT OWNER |
Petitioner’s Responsive Brief to Patent Owner’s Opening Brief on Additional Claim Construction (Paper 93) | Nov 13, 2023 | PAPER | PETITIONER |
Patent Owner's Opposition to Paper 94 | Nov 13, 2023 | PAPER | PATENT OWNER |
Patent Owner's Opening Brief on Additional Claim Construction | Nov 3, 2023 | PAPER | PATENT OWNER |
Petitioner's Brief in Response to the Board's Order Regarding the Construction of the Claim Term “Effective Sequential Dosing Regimen” | Nov 3, 2023 | PAPER | PETITIONER |
Conduct of the Proceeding 37 C.F.R. § 42.5 | Oct 27, 2023 | PAPER | BOARD |
Order: ORDER Granting Patent Owner’s Unopposed Motion for Entry of Default Protective Order 37 C.F.R. § 42.54 | Oct 27, 2023 | PAPER | BOARD |
Patent Owner's Corrected Statement of Objections to Petitioner's Demonstratives | Oct 24, 2023 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Oct 24, 2023 | PAPER | PATENT OWNER |
Ex. 2351 - Patent Owners Updated Demonstratives | Oct 24, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Statement of Objections to Petitioner's Demonstratives | Oct 23, 2023 | PAPER | PATENT OWNER |
Petitioner's Statement of Objections to Patent Owner's Demonstratives | Oct 23, 2023 | PAPER | PETITIONER |
Patent Owner's Updated Exhibit List | Oct 20, 2023 | PAPER | PATENT OWNER |
Ex. 2350 - Patent Owner's Demonstratives | Oct 20, 2023 | EXHIBIT | PATENT OWNER |
Petitioner's Updated Exhibit List | Oct 20, 2023 | PAPER | PETITIONER |
Ex. 1173 - Petitioner's Demonstratives | Oct 20, 2023 | EXHIBIT | PETITIONER |
Petitioner's Reply to PO's Opposition to Motion to Exclude | Oct 4, 2023 | PAPER | PETITIONER |
Patent Owner's Reply to Opposition to Motion to Exclude | Oct 4, 2023 | PAPER | PATENT OWNER |
Order: Setting Oral Argument - 37 CFR 42.70 | Sep 27, 2023 | PAPER | BOARD |
Patent Owner's Opposition to Petitioner's Motion to Exclude Evidence | Sep 27, 2023 | PAPER | PATENT OWNER |
Ex. 2349 - Transcript of Deposition of Jeffrey Spada | Sep 27, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Exhibit List | Sep 27, 2023 | PAPER | PATENT OWNER |
Petitioner's Opposition to Patent Owner's Motion to Exclude | Sep 27, 2023 | PAPER | PETITIONER |
Exhibit 3002 | Sep 26, 2023 | EXHIBIT | BOARD |
Petitioner's Motion to Seal | Sep 20, 2023 | PAPER | PETITIONER |
Petitioner's Motion to Exclude Evidence - CONFIDENTIAL | Sep 20, 2023 | PAPER | PETITIONER |
Patent Owner's Motion to Exclude | Sep 20, 2023 | PAPER | PATENT OWNER |
Petitioner's Motion to Exclude Evidence - REDACTED | Sep 20, 2023 | PAPER | PETITIONER |
ORDER Granting Patent Owner’s Motions for Admission Pro Hac Vice of Daralyn J. Durie | Sep 18, 2023 | PAPER | BOARD |
Patent Owner's Motion for Pro Hac Vice Admission of Daralyn Durie | Sep 12, 2023 | PAPER | PATENT OWNER |
Ex. 2348 - Declaration of Daralyn Durie | Sep 12, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Power of Attorney | Sep 12, 2023 | PAPER | PATENT OWNER |
Patent Owner's Amended Mandatory Notices | Sep 12, 2023 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Sep 12, 2023 | PAPER | PATENT OWNER |
Patent Owner's Request for Oral Argument | Aug 30, 2023 | PAPER | PATENT OWNER |
Petitioners' Request for Oral Argument | Aug 30, 2023 | PAPER | PETITIONER |
Petitioner's Fourth Objections to Patent Owner's Exhibits | Aug 16, 2023 | PAPER | PETITIONER |
Ex. 2346 [REDACTED] Transcript of Deposition of Ivan Hofmann, July 13, 2023 | Aug 10, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Sur-Reply | Aug 9, 2023 | PAPER | PATENT OWNER |
Ex. 2346 [CONFIDENTIAL] Transcript of Deposition of Ivan Hofmann, July 13, 2023 | Aug 9, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2347 - Transcript of Deposition of Thomas Albini, July 20, 2023 | Aug 9, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Motion to Seal | Aug 9, 2023 | PAPER | PATENT OWNER |
Patent Owner's Amended Notice of Deposition of Ivan T. Hofmann, C.P.A., C.F.F., C.L.P. | Jul 7, 2023 | PAPER | PATENT OWNER |
Patent Owner's Notice of Deposition of Dr. Thomas A. Albini | Jul 7, 2023 | PAPER | PATENT OWNER |
Patent Owner's Second Set of Objections to Petitioner's Exhibits | Jul 6, 2023 | PAPER | PATENT OWNER |
Notice of Deposition of Ivan T. Hofmann | Jul 3, 2023 | PAPER | PATENT OWNER |
Ex. 1106 - Monthly Dosing Patents | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1107 - Albini Reply Declaration (IPR2022-01226) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1110 - Brown Deposition Transcript | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1112 - Markman Order | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1113 - WHO Drug Info | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1114 - Hofmann CV | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1116 - ASRS Clinical Update | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1117 - Drugs@FDA - Eylea | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1119 - Regeneron 2011 10-K | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1122 - Eylea Label (2.23) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1123 - Eylea Patent List | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1124 - Complaint (6.24.20).pdf | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1125 - Eylea Label (5.16) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1126 - ’261 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1127 - '598 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1128 - '791 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1129 - '803 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1130 - '737 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1131 - '842 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1132 - '226 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1133 - '992 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1134 - '345 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1135 - '458 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1136 - '865 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1137 - '572 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1138 - Collaboration Agreement | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1139 - Regeneron 2004 10-K | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1140 - Regeneron 2013 10-Q | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1141 - Purple Book List | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1142 - United Healthcare - Ophthalmologic VEGF Inhibitors | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1143 - BCBS Florida VEGF | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1144 - Eylea Summary Review | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1145 - mygoodays.org (CDF) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1146 - mygooddays.org (Assistance Types) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1147 - Official EYLEA (aflibercept) Injection Website | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1149 - Bayer and Regeneron to Collaborate on VEGF Trap | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1150 - Complaint (Horizon v. Regeneron, 4.22) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (1 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (2 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (3 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (4 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (5 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (6 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (7 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (8 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1151 - U.S. Statement of Facts (9 of 9) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1152 - oig.hhs.gov (Publication of OIG Special Fraud Alerts) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1153 - MorganLewis - New Purple Book Patent Requirements | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1154 - Fierce Pharma – JPM23 | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1155 - Accord Case | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1156 - Regeneron Stipulation | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1157 - Medicare Comment Summary | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1158 - '563 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1159 - '653 patent | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1160 - Lucentis EMA | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1161 - Optometry Pharma | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1162 - Fauser | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1163 - Do | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1164 - Batta | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1165 - Stewart 2008 | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1166 - Bhisitkul & Stewart 2010 | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1167 - Gerritsen Reply Declaration (IPR2022-01226) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1168 - PAT Survey 2010 | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1169 - Dadgostar | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1170 - CATT Study | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1171 - NCT00685854 (5.24.08) | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1172 - MACTEL Study Wayback Machine | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1118 - Regeneron 2005 10-K | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1111 - Joint Stipulation | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1108 - Klibanov Deposition Transcript [CONFIDENTIAL] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1108 - Klibanov Deposition Transcript [REDACTED] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1109 - Do Deposition Transcript [CONFIDENTIAL] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1109 - Do Deposition Transcript [REDACTED] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1115 - Hofmann Reply Declaration (IPR2022-01226) [REDACTED] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1115 - Hofmann Reply Declaration (IPR2022-01226) [CONFIDENTIAL] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1120 - Manning Deposition Transcript (5.4.22) [REDACTED] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1120 - Manning Deposition Transcript (5.4.22) [CONFIDENTIAL] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1121 - Manning Deposition Transcript (6.1.23) [REDACTED] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Ex. 1121 - Manning Deposition Transcript (6.1.23) [CONFIDENTIAL] | Jun 29, 2023 | EXHIBIT | PETITIONER |
Petitioner Reply (IPR2022-01226) [REDACTED] | Jun 29, 2023 | PAPER | PETITIONER |
Petitioner Reply (IPR2022-01226) [CONFIDENTIAL] | Jun 29, 2023 | PAPER | PETITIONER |
Petitioner's Amended Mandatory Notices | May 18, 2023 | PAPER | PETITIONER |
Dr. Manning Notice of Deposition | May 18, 2023 | PAPER | PETITIONER |
Notice of Deposition of Dr. Diana Do | May 10, 2023 | PAPER | PETITIONER |
Notice of Deposition of Jeffrey Spada | May 10, 2023 | PAPER | PETITIONER |
Notice of Deposition of Jennifer Colyer | May 10, 2023 | PAPER | PETITIONER |
Dr. Brown Notice of Deposition | May 4, 2023 | PAPER | PETITIONER |
Dr. Klibanov Notice of Deposition | May 4, 2023 | PAPER | PETITIONER |
Petitioner's Third Objections to Patent Owner's Exhibits | May 3, 2023 | PAPER | PETITIONER |
Patent Owner's Amended Mandatory Notices | May 3, 2023 | PAPER | PATENT OWNER |
Petitioner's Second Objections to Patent Owner's Exhibits | Apr 12, 2023 | PAPER | PETITIONER |
Petitioner's Amended Mandatory Notices | Apr 10, 2023 | PAPER | PETITIONER |
Patent Owner's Motion to Seal | Apr 5, 2023 | PAPER | PATENT OWNER |
Patent Owner's Response [CONFIDENTIAL] | Apr 5, 2023 | PAPER | PATENT OWNER |
Patent Owner's Response [REDACTED] | Apr 5, 2023 | PAPER | PATENT OWNER |
CV of Dr. Diana V. Do | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2018 - Genentech Press Release | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2019 - McGregor N. Lott et al., Bevacizumab in Inflammatory Eye Disease | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2020 - Ahmad M. Mansour et al., Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2021 - Transcript of Deposition of Thomas Albini (Jan. 2022) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2022 - Transcript of Deposition of Thomas Albini (Jun. 2022) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2023 - Matthew Ohr et al., Aflibercept in wet age-related macular degeneration: a perspective review | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2024 - U.S. Publication No. 2007/0190058 A1 (“Shams”) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2025 - Drugs@FDA, Macugen Label, 12/2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2026 - Expert Declaration of Dr. Thomas A. Albini in Support of Petitioner’s Reply [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2027 - Patent Owners Demonstratives for Oral Argument from IPR2021-00880 & -00881 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2028 - Albini Declaration re 069 patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2029 - Robert Steinbrook, The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2030 - Side-by-side Exclusion Criteria Comparison VIEW vs ANCHOR MARINA | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2031 - Macugen Medical Review | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2032 - Regeneron Press Release Feb. 14, 2013 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2033 - Regeneron Press Release Feb. 6, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2034 - FiercePharma 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2035 - CDER Statistical Review | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2036 - Transcript of Deposition of David M. Brown (Apr. 2022) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2037 - Regeneron ATU Sales Share Data - Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2038 - | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2039 - Eylea Marketing Material Nov. 2013 part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2039 - Eylea Marketing Material Nov. 2013 part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2040 - Regeneron Earnings Call Transcript Feb. 13, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2041 - PUBLIC Hofmann Deposition Transcript part 1 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2041 - PUBLIC Hofmann Deposition Transcript part 2 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2041 - PUBLIC Hofmann Deposition Transcript part 3 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2042 - Albini Declaration re 338 patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2043 - Gerritsen Declaration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2044 - Gerritsen Deposition Transcript | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2055 - Expert Declaration of David M. Brown, M.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2056 - Expert Declaration of Dr. Diana V. Do, M.D. [CONFIDENTIAL] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2056 - Expert Declaration of Dr. Diana V. Do, M.D. [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2057 - Expert Declaration of Dr. Alexander M. Klibanov, Ph.D. [CONFIDENTIAL] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2057 - Expert Declaration of Dr. Alexander M. Klibanov, Ph.D. [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2058 - Expert Declaration of Richard Manning, Ph.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2059 - Expert Declaration of Richard Manning, Ph.D. from IPR2021-00881 {CONFIDENTIAL] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2059 - Expert Declaration of Richard Manning, Ph.D. from IPR2021-00881 [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2060 - CV of Dr. David Mark Brown, M.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2061 - CV of Dr. Alexander M. Klibanov, Ph.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2062 - Excerpts from SHORTER OXFORD ENGLISH DICTIONARY VOL. 1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2063 - Eylea Prescribing Information | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2064 - Eylea Approval Letter | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2065 - Biochemistry 2002 5 ed | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2066 - Organic Chemistry 4th ed Chap 27 - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2066 - Organic Chemistry 4th ed Chap 27 - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2067 - Hirokawa 1988 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2068 - Prange 1998 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2069 - Mihailescu 2001 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2070 - Beek 2002 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2071 - Handgraaf 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2072 - Yu 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2073 - Scott 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2074 - Kleiger 2000 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2075 - Demarest 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2076 - Cantu 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2077 - Biochemistry 6th ed Chap 7 - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2077 - Biochemistry 6th ed Chap 7 - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2078 - Davis-Smyth 1996 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2079 - UNIPROT - P17948 VGFR1 Human | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2080 - UNIPROT - P17948 v140 -2011-01-11 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2081 - Weissmann 1997 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2082 - Lu 2000 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2083 - Franklin 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2084 - UNIPROT - P35968 VGFR2 Human | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2085 - UNIPROT - P35968 v127 -2011-01-11 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2086 - Bowie - domain1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2087 - US Pub 2006_0058234 A1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2088 - lacono 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2089 - Stewart & Rosenfeld 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2090 - Do 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2091 - Moroney 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2092 - US Pub 2010_0160233 A1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2093 - Hachiya 2007 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2094 - Piques 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2095 - WO 2000_075319 A1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2096 - Kuhlmann 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2097 - Murphy 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2098 - [CONFIDENTIAL] Zaltrap non-comparability | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2099 - Bork 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2100 - Sola 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2101 - [CONFIDENTIAL] Koehler-Stec Report | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2102 - Wells 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2106 - Macugen Approval Letter | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2107 - 2004 Macugen Label | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2108 - Brown DM, et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2109 - Rosenfeld 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2110 - Genentech Press Release Dec. 30, 2005 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2111 - Genentech Press Release June 30, 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2112 - NCT00473330 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2113 - NCT00473382 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2114 - NCT00486018 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2115 - NCT00485836 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2116 - NCT00943072 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2117 - NCT01012973 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2118 - FDA Non-Inferiority Clinical Trials | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2119 - May 2016 Eylea Label | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2120 AAO | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2121 - Jaffe 2016 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2122 - [CONFIDENTIAL] VGFT-OD-0605 Analysis Summary | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2123 - 2009 version of NCT00826618 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2124 Investigative Ophthalmology & Visual Science | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2125 - 2014 version of NCT00826618 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2126 - BenEzra | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2127 - Ramirez | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2128 - Adamis Chapter 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2129 - Brown 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2130 - Gragoudas 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2131 - Regillo 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2132 - Levine 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2134 - Regeneron Earnings Call Tr Apr 26, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2135 - Regeneron Earnings Call Tr July 25, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2136 - Eylea Marketing Material, 2013 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2138 - [CONFIDENTIAL] Regeneron Physician ATU Wave 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
EXPUNGED | Apr 5, 2023 | PAPER | PATENT OWNER |
Ex. 2139 - Regeneron For the Treatment of Wet AMD, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2140 - [CONFIDENTIAL] Regeneron Physician ATU Wave 5 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2141 - Am. Acad. of Ophthalmol. - Anti-VEGF Treatments | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2142 - Am. Acad. of Ophthalmol. - Bevacizumab | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2143 - Am. Acad. of Ophthalmol. - Ophthalmology Subspecialists | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2144 - Am. Acad. of Ophthalmol. - Retinal Vasculitis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2145 - Am. Acad. of Ophthalmol. - What Is Avastin | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2146 - Am. Acad. of Ophthalmol. - What Is Eylea | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2147 - Am. Acad. of Ophthalmol. - What Is Lucentis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2148 - Am. Soc. of Retina Specialists - About Us | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2149 - Am. Soc. of Retina Specialists - Age-Related Macular Degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2150 - Am. Soc. of Retina Specialists - Branch Retinal Vein Occlusion | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2151 - Am. Soc. of Retina Specialists - Central Retinal Vein Occlusion | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2152 - Am. Soc. of Retina Specialists - Diabetic Retinopathy | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2153 - Amgen - Fusion Protein | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2154 - ASHA - Calculating Medicare Fee Schedule Rates | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2155 - ASPE Issue Brief - Medicare Part B Reimbursement of Prescription Drugs | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2156 - Avastin Drug Label 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2157 - Base Pair Biotechnologies - What is an Aptamer | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2158 - Bausch and Lomb Website - Visudyne | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2159 - Bausch and Lomb Website - Visudyne Saftey Information | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2160 - Bausch Health Companies 10-K, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2161 - Beovu Drug Label Oct. 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2162 - Beovu Drug Label June 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2163 - [CONFIDENTIAL] Regeneron Physician ATU Wave 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2164 - BrightFocus Foundation - AMD Facts & Figures | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2165 - Brookings - Medicare Payment for Physician-Administered (Part B) Drugs | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2166 - Calculator.net - Sample Size Calculator | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2167 - CDC - Vision Loss - A Public Health Problem | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2168 - Centers for Medicare & Medicaid Services Data - Practitioners | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 1 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 2 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 3 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 4 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2170 - [CONFIDENTIAL] US Eylea P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2170 - [REDACTED] US Eylea P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2171 - CloudResearch - Determining Sample Size | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2172 - CMS - 2021 ASP Drug Pricing Files | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2173 - CMS - Medicare Part B Drug Average Sales Price | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2174 - CMS - Physician Fee Schedule | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2175 - CMS Medicare Coverage Database - Billing and Coding Afilbercept | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2176 - [CONFIDENTIAL] Regeneron Q4 Performance Update | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2177 - Donahue 2007 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2178 - Donohue 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2179 - Dreyfuss 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2180 - Miller 2020. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2181 - Drugs.com - Eylea FDA Approval History | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2182 - Elyasi 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2183 - Eye Care Surgery Center - Macular Degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2184 - EyeGuru - Intravitreal Injection Standard Dosing Table | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2185 - Eylea Drug Label Nov. 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2186 - Eylea Drug Label Sept. 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2187 - Eylea Drug Label Oct. 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2188 - Eylea Drug Label May 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2189 - Eylea Drug Label Mar. 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2190 - Eylea Website - Dosing Flexibility for Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2191 - FDA Website - Drug Approval Package Macugen | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2192 - FiercePharma - Beovu, Novartis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2193 - FiercePharma - Novartis Drug Beovu Tied to Potential Vision Loss | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2194 - FiercePharma - The top 20 drugs by worldwide sales in 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2195 - FocusVision - Survey Sample Size How Much Do I Need | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2196 - Gagnon 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2197 - [CONFIDENTIAL] Eylea Physician ATU Benchmark Wave | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2198 - GEN - FDA Green-Lights Genentechs Lucentis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2199 - Genentech Press Release June 30, 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2200 - [CONFIDENTIAL] Regeneron US Eylea Historical PL | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2200 - [REDACTED] Regeneron US Eylea Historical PL | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2201 - Guha 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2202 - HCPCS Codes - HCPCS Codes | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2203 - Healio - Access to retina providers shows no geographic bias in US | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2204 - Hopkins Medicine Website - Photodynamic Therapy for AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2205 - [CONFIDENTIAL] Eylea DME Market Assessment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2206 - IQVIA 10-K 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2207 - IQVIA - Available IQVIA Data | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2208 - [CONFIDENTIAL] Eylea ATU Wave 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2209 - KFF - A Snapshot of Sources of Coverage Among Medicare Beneficiaries in 2018 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2210 - KFF - Medicare Advantage in 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2211 - Ling 2002 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2212 - Lucentis Drug Label 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2213 - Lucentis Drug Label June 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2214 - Lucentis Drug Label Aug. 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2215 - Lucentis Drug Label Apr. 2017 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2216 - Lucentis Drug Label Mar. 2018 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2218 - [CONFIDENTIAL] Eylea Components of Reimbursement | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2218 - [REDACTED] Eylea Components of Reimbursement | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2219 - Mankiw Chapter 1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2220 - Manning 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2221 - Mayo Clinic - Wet macular degeneration - Diagnosis and treatment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2222 - Mayo Clinic - Wet macular degeneration - Symptoms and Causes | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2223 - Medicare Interactive - Medicare Part B Covered Services | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2224 - Medicare Interactive - The parts of Medicare (A, B, C, D) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2225 - Medicare.gov - Macular Degeneration Coverage | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2226 - Medicare.gov - Medicare Advantage Plans | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2227 - Medicare.gov - When does Medicare coverage start | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2228 - MedlinePlus Medical Encyclopedia - Laser photocoagulation | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2229 - [CONFIDENTIAL] Regeneron WAC Pricing | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2230 - Novartis - Annual Report, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2231 - Novartis Press Release Oct. 8, 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2232 - Novartis Press Release June 11, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2233 - Oct 12 ASP Pricing File revised 060513 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2234 - Oct 13 ASP Pricing File updated 060614 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2235 - Oct 15 ASP Pricing File - updated 120915 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2236 - Oct 16 ASP Pricing File updated 082817 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2237 - Oct 17 ASP Pricing File 083017 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2238 - Oct 18 ASP Pricing File updated 052919 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2239 - Oct 2019 ASP Pricing File 052920 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2240 - Oct 14 ASP Pricing File - revised 090115 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2241 - October 2020 ASP Pricing File updated 090121 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2242 - October 2021 ASP Pricing File updated 011022 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2243 - [CONFIDENTIAL] ASRS Preferences & Trends Survey 2016 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2244 - [CONFIDENTIAL] ASRS Preferences & Trends Survey 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2245 - Pindyck Chapter 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2246 - Regeneron - About Us | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2247 - Regeneron Press Release July 29, 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2248 - Regeneron Press Release Oct. 6, 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2249 - Regeneron Press Release May 13, 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2250 - [CONFIDENTIAL] ASRS Prefernces & Trends Survey 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2251 - Regeneron - History | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2252 - Regeneron Press Release Sept. 21, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2253 - Regeneron - Research Areas | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2254 - Regeneron Form 10-K for 2020 - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2254 - Regeneron Form 10-K for 2020 - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2255 - Retinal Physician - Revisiting an Early Treatment for Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2256 - Roche 10-K, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2257 - Roche Press Release Aug. 13, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2258 - Roche Press Release Apr. 18, 2017 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2259 - [CONFIDENTIAL] ASRS Preferences & Trends Survey 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2260 - Schweitzer Chapter 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2261 - ScienceDaily - FDA Approves First Angiogenesis Inhibitor | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2262 - Sivaprasad 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2263 - [CONFIDENTIAL] Eylea Sales Summary | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2264 - Verywell Health - Maclular Degeneration Timeline | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2265 - Vestrum Health - Explore what we can do for you | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2266 - Vestrum Health - Pharmaceutical companies | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2267 - Visudyne Drug Label Apr 2016 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2268 - Weidner 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2269 - WHO - Blindness and vision impairment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2270 - Yahoo Finance - Beovu Now Publicly Reimbursed | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2271 - Yorston 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2272 - [CONFIDENTIAL] Eylea Q2 2021 Performance | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2273 - [CONFIDENTIAL] Vestrum Anti-VEGF Category Sales Shares | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2274 - [CONFIDENTIAL] Eylea Wet AMD Line of Therapy Insights | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2275 - [CONFIDENTIAL] Vestrum Anti-VEGF Market Share Adjustment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2276 - [CONFIDENTIAL] Eylea Q2 2020 Performance | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2277 - [CONFIDENTIAL] Regeneron Marketing Planning Process | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2278 - [CONFIDENTIAL] Regeneron Wave 1 2021 Performance Update | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2279 - Regeneron ATU Sales Share Data - All Indications | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2282 - Regeneron ATU Sales Share Data - CRVO | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2283 - Regeneron ATU Sales Share Data - BRVO | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2284 - Regeneron ATU Sales Share Data - DR without DME | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2285 - [CONFIDENTIAL] Eylea Gross & Net Sales P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2285 - [REDACTED] Eylea Gross & Net Sales P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2286 - Abraham 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2287 - Barbazetto 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2288 - Daniele Cruz, PIER Data Suggest a Need for Tailored Injection Schedule, Ocular Surgery News | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
EXPUNGED | Apr 5, 2023 | PAPER | PATENT OWNER |
CV of Dr. Diana V. Do | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2018 - Genentech Press Release | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2019 - McGregor N. Lott et al., Bevacizumab in Inflammatory Eye Disease | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2020 - Ahmad M. Mansour et al., Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2021 - Transcript of Deposition of Thomas Albini (Jan. 2022) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2022 - Transcript of Deposition of Thomas Albini (Jun. 2022) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2023 - Matthew Ohr et al., Aflibercept in wet age-related macular degeneration: a perspective review | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2024 - U.S. Publication No. 2007/0190058 A1 (“Shams”) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2025 - Drugs@FDA, Macugen Label, 12/2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2026 - Expert Declaration of Dr. Thomas A. Albini in Support of Petitioner’s Reply [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2027 - Patent Owners Demonstratives for Oral Argument from IPR2021-00880 & -00881 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2028 - Albini Declaration re 069 patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2029 - Robert Steinbrook, The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2030 - Side-by-side Exclusion Criteria Comparison VIEW vs ANCHOR MARINA | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2031 - Macugen Medical Review | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2032 - Regeneron Press Release Feb. 14, 2013 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2033 - Regeneron Press Release Feb. 6, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2034 - FiercePharma 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2035 - CDER Statistical Review | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2036 - Transcript of Deposition of David M. Brown (Apr. 2022) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2037 - Regeneron ATU Sales Share Data - Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2038 - | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2039 - Eylea Marketing Material Nov. 2013 part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2039 - Eylea Marketing Material Nov. 2013 part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2040 - Regeneron Earnings Call Transcript Feb. 13, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2041 - PUBLIC Hofmann Deposition Transcript part 1 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2041 - PUBLIC Hofmann Deposition Transcript part 2 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2041 - PUBLIC Hofmann Deposition Transcript part 3 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2042 - Albini Declaration re 338 patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2043 - Gerritsen Declaration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2044 - Gerritsen Deposition Transcript | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2055 - Expert Declaration of David M. Brown, M.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2056 - Expert Declaration of Dr. Diana V. Do, M.D. [CONFIDENTIAL] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2056 - Expert Declaration of Dr. Diana V. Do, M.D. [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2057 - Expert Declaration of Dr. Alexander M. Klibanov, Ph.D. [CONFIDENTIAL] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2057 - Expert Declaration of Dr. Alexander M. Klibanov, Ph.D. [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2058 - Expert Declaration of Richard Manning, Ph.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2059 - Expert Declaration of Richard Manning, Ph.D. from IPR2021-00881 {CONFIDENTIAL] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2059 - Expert Declaration of Richard Manning, Ph.D. from IPR2021-00881 [REDACTED] | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2060 - CV of Dr. David Mark Brown, M.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2061 - CV of Dr. Alexander M. Klibanov, Ph.D. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2062 - Excerpts from SHORTER OXFORD ENGLISH DICTIONARY VOL. 1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2063 - Eylea Prescribing Information | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2064 - Eylea Approval Letter | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2065 - Biochemistry 2002 5 ed | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2066 - Organic Chemistry 4th ed Chap 27 - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2066 - Organic Chemistry 4th ed Chap 27 - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2067 - Hirokawa 1988 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2068 - Prange 1998 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2069 - Mihailescu 2001 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2070 - Beek 2002 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2071 - Handgraaf 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2072 - Yu 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2073 - Scott 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2074 - Kleiger 2000 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2075 - Demarest 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2076 - Cantu 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2077 - Biochemistry 6th ed Chap 7 - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2077 - Biochemistry 6th ed Chap 7 - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2078 - Davis-Smyth 1996 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2079 - UNIPROT - P17948 VGFR1 Human | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2080 - UNIPROT - P17948 v140 -2011-01-11 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2081 - Weissmann 1997 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2082 - Lu 2000 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2083 - Franklin 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2084 - UNIPROT - P35968 VGFR2 Human | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2085 - UNIPROT - P35968 v127 -2011-01-11 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2086 - Bowie - domain1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2088 - lacono 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2089 - Stewart & Rosenfeld 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2090 - Do 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2091 - Moroney 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2092 - US Pub 2010_0160233 A1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2093 - Hachiya 2007 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2094 - Piques 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2095 - WO 2000_075319 A1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2096 - Kuhlmann 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2097 - Murphy 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2098 - [CONFIDENTIAL] Zaltrap non-comparability | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2099 - Bork 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2100 - Sola 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2101 - [CONFIDENTIAL] Koehler-Stec Report | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2102 - Wells 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2106 - Macugen Approval Letter | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2107 - 2004 Macugen Label | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2108 - Brown DM, et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2109 - Rosenfeld 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2110 - Genentech Press Release Dec. 30, 2005 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2111 - Genentech Press Release June 30, 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2112 - NCT00473330 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2113 - NCT00473382 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2114 - NCT00486018 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2115 - NCT00485836 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2116 - NCT00943072 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2117 - NCT01012973 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2118 - FDA Non-Inferiority Clinical Trials | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2119 - May 2016 Eylea Label | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2120 AAO | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2121 - Jaffe 2016 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2122 - [CONFIDENTIAL] VGFT-OD-0605 Analysis Summary | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2123 - 2009 version of NCT00826618 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2124 Investigative Ophthalmology & Visual Science | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2125 - 2014 version of NCT00826618 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2126 - BenEzra | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2127 - Ramirez | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2128 - Adamis Chapter 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2129 - Brown 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2130 - Gragoudas 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2131 - Regillo 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2132 - Levine 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2134 - Regeneron Earnings Call Tr Apr 26, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2135 - Regeneron Earnings Call Tr July 25, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2136 - Eylea Marketing Material, 2013 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2138 - [CONFIDENTIAL] Regeneron Physician ATU Wave 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2139 - Regeneron For the Treatment of Wet AMD, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2140 - [CONFIDENTIAL] Regeneron Physician ATU Wave 5 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2141 - Am. Acad. of Ophthalmol. - Anti-VEGF Treatments | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2142 - Am. Acad. of Ophthalmol. - Bevacizumab | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2143 - Am. Acad. of Ophthalmol. - Ophthalmology Subspecialists | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2144 - Am. Acad. of Ophthalmol. - Retinal Vasculitis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2145 - Am. Acad. of Ophthalmol. - What Is Avastin | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2146 - Am. Acad. of Ophthalmol. - What Is Eylea | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2147 - Am. Acad. of Ophthalmol. - What Is Lucentis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2148 - Am. Soc. of Retina Specialists - About Us | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2149 - Am. Soc. of Retina Specialists - Age-Related Macular Degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2150 - Am. Soc. of Retina Specialists - Branch Retinal Vein Occlusion | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2151 - Am. Soc. of Retina Specialists - Central Retinal Vein Occlusion | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2152 - Am. Soc. of Retina Specialists - Diabetic Retinopathy | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2153 - Amgen - Fusion Protein | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2154 - ASHA - Calculating Medicare Fee Schedule Rates | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2155 - ASPE Issue Brief - Medicare Part B Reimbursement of Prescription Drugs | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2156 - Avastin Drug Label 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2157 - Base Pair Biotechnologies - What is an Aptamer | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2158 - Bausch and Lomb Website - Visudyne | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2159 - Bausch and Lomb Website - Visudyne Saftey Information | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2160 - Bausch Health Companies 10-K, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2161 - Beovu Drug Label Oct. 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2162 - Beovu Drug Label June 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2163 - [CONFIDENTIAL] Regeneron Physician ATU Wave 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2164 - BrightFocus Foundation - AMD Facts & Figures | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2165 - Brookings - Medicare Payment for Physician-Administered (Part B) Drugs | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2166 - Calculator.net - Sample Size Calculator | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2167 - CDC - Vision Loss - A Public Health Problem | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2168 - Centers for Medicare & Medicaid Services Data - Practitioners | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 1 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 2 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 3 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2169 - [CONFIDENTIAL] Eylea Sample Disbursement - Part 4 of 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2170 - [CONFIDENTIAL] US Eylea P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2170 - [REDACTED] US Eylea P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2171 - CloudResearch - Determining Sample Size | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2172 - CMS - 2021 ASP Drug Pricing Files | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2173 - CMS - Medicare Part B Drug Average Sales Price | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2174 - CMS - Physician Fee Schedule | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2175 - CMS Medicare Coverage Database - Billing and Coding Afilbercept | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2176 - [CONFIDENTIAL] Regeneron Q4 Performance Update | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2177 - Donahue 2007 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2178 - Donohue 2004 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2179 - Dreyfuss 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2180 - Miller 2020. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2181 - Drugs.com - Eylea FDA Approval History | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2182 - Elyasi 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2183 - Eye Care Surgery Center - Macular Degeneration | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2184 - EyeGuru - Intravitreal Injection Standard Dosing Table | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2185 - Eylea Drug Label Nov. 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2186 - Eylea Drug Label Sept. 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2187 - Eylea Drug Label Oct. 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2188 - Eylea Drug Label May 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2189 - Eylea Drug Label Mar. 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2190 - Eylea Website - Dosing Flexibility for Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2191 - FDA Website - Drug Approval Package Macugen | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2192 - FiercePharma - Beovu, Novartis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2193 - FiercePharma - Novartis Drug Beovu Tied to Potential Vision Loss | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2194 - FiercePharma - The top 20 drugs by worldwide sales in 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2195 - FocusVision - Survey Sample Size How Much Do I Need | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2196 - Gagnon 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2197 - [CONFIDENTIAL] Eylea Physician ATU Benchmark Wave | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2198 - GEN - FDA Green-Lights Genentechs Lucentis | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2199 - Genentech Press Release June 30, 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2200 - [CONFIDENTIAL] Regeneron US Eylea Historical PL | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2200 - [REDACTED] Regeneron US Eylea Historical PL | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2201 - Guha 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2202 - HCPCS Codes - HCPCS Codes | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2203 - Healio - Access to retina providers shows no geographic bias in US | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2204 - Hopkins Medicine Website - Photodynamic Therapy for AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2205 - [CONFIDENTIAL] Eylea DME Market Assessment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2206 - IQVIA 10-K 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2207 - IQVIA - Available IQVIA Data | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2208 - [CONFIDENTIAL] Eylea ATU Wave 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2209 - KFF - A Snapshot of Sources of Coverage Among Medicare Beneficiaries in 2018 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2210 - KFF - Medicare Advantage in 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2211 - Ling 2002 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2212 - Lucentis Drug Label 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2213 - Lucentis Drug Label June 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2214 - Lucentis Drug Label Aug. 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2215 - Lucentis Drug Label Apr. 2017 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2216 - Lucentis Drug Label Mar. 2018 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2218 - [CONFIDENTIAL] Eylea Components of Reimbursement | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2218 - [REDACTED] Eylea Components of Reimbursement | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2219 - Mankiw Chapter 1 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2220 - Manning 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2221 - Mayo Clinic - Wet macular degeneration - Diagnosis and treatment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2222 - Mayo Clinic - Wet macular degeneration - Symptoms and Causes | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2223 - Medicare Interactive - Medicare Part B Covered Services | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2224 - Medicare Interactive - The parts of Medicare (A, B, C, D) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2225 - Medicare.gov - Macular Degeneration Coverage | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2226 - Medicare.gov - Medicare Advantage Plans | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2227 - Medicare.gov - When does Medicare coverage start | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2228 - MedlinePlus Medical Encyclopedia - Laser photocoagulation | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2229 - [CONFIDENTIAL] Regeneron WAC Pricing | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2230 - Novartis - Annual Report, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2231 - Novartis Press Release Oct. 8, 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2232 - Novartis Press Release June 11, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2233 - Oct 12 ASP Pricing File revised 060513 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2234 - Oct 13 ASP Pricing File updated 060614 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2235 - Oct 15 ASP Pricing File - updated 120915 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2236 - Oct 16 ASP Pricing File updated 082817 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2237 - Oct 17 ASP Pricing File 083017 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2238 - Oct 18 ASP Pricing File updated 052919 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2239 - Oct 2019 ASP Pricing File 052920 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2240 - Oct 14 ASP Pricing File - revised 090115 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2241 - October 2020 ASP Pricing File updated 090121 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2242 - October 2021 ASP Pricing File updated 011022 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2243 - [CONFIDENTIAL] ASRS Preferences & Trends Survey 2016 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2244 - [CONFIDENTIAL] ASRS Preferences & Trends Survey 2015 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2245 - Pindyck Chapter 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2246 - Regeneron - About Us | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2247 - Regeneron Press Release July 29, 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2248 - Regeneron Press Release Oct. 6, 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2249 - Regeneron Press Release May 13, 2019 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2250 - [CONFIDENTIAL] ASRS Prefernces & Trends Survey 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2251 - Regeneron - History | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2252 - Regeneron Press Release Sept. 21, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2253 - Regeneron - Research Areas | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2254 - Regeneron Form 10-K for 2020 - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2254 - Regeneron Form 10-K for 2020 - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2255 - Retinal Physician - Revisiting an Early Treatment for Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2256 - Roche 10-K, 2020 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2257 - Roche Press Release Aug. 13, 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2258 - Roche Press Release Apr. 18, 2017 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2259 - [CONFIDENTIAL] ASRS Preferences & Trends Survey 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2260 - Schweitzer Chapter 4 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2261 - ScienceDaily - FDA Approves First Angiogenesis Inhibitor | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2262 - Sivaprasad 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2263 - [CONFIDENTIAL] Eylea Sales Summary | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2264 - Verywell Health - Maclular Degeneration Timeline | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2265 - Vestrum Health - Explore what we can do for you | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2266 - Vestrum Health - Pharmaceutical companies | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2267 - Visudyne Drug Label Apr 2016 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2268 - Weidner 2021 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2269 - WHO - Blindness and vision impairment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2270 - Yahoo Finance - Beovu Now Publicly Reimbursed | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2271 - Yorston 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2272 - [CONFIDENTIAL] Eylea Q2 2021 Performance | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2273 - [CONFIDENTIAL] Vestrum Anti-VEGF Category Sales Shares | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2274 - [CONFIDENTIAL] Eylea Wet AMD Line of Therapy Insights | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2275 - [CONFIDENTIAL] Vestrum Anti-VEGF Market Share Adjustment | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2276 - [CONFIDENTIAL] Eylea Q2 2020 Performance | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2277 - [CONFIDENTIAL] Regeneron Marketing Planning Process | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2278 - [CONFIDENTIAL] Regeneron Wave 1 2021 Performance Update | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2279 - Regeneron ATU Sales Share Data - All Indications | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2282 - Regeneron ATU Sales Share Data - CRVO | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2283 - Regeneron ATU Sales Share Data - BRVO | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2284 - Regeneron ATU Sales Share Data - DR without DME | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2285 - [CONFIDENTIAL] Eylea Gross & Net Sales P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2285 - [REDACTED] Eylea Gross & Net Sales P&L | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2286 - Abraham 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2287 - Barbazetto 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2288 - Daniele Cruz, PIER Data Suggest a Need for Tailored Injection Schedule, Ocular Surgery News | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2289 - Retinal Physician Symposium | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2290 - Lucentis Label 2006 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2291 - Schmidt-Erfuth 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2293 - Margolis 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2294 -Park 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2295 - Spaide 2007 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2296 - Brown 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2297 - Heier 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2298 - [CONFIDENTIAL] Research Agreement | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2299 - [CONFIDENTIAL] VGFT-OD-0605 Protocol Signature Page | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2300 - Eylea P I | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2301 - Regeneron Corrected Press Release Nov. 18, 2011 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2302 - Eylea Approval Letter | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2303 - Bhisitkul & Stewart 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2304 - FDA 22 Case Studies | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2305 -NCT02247531 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2306 -NCT02247479 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2307 -NCT03577899 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2308 - NCT03630952 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2309 -NCT01944839 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2310 - NCT01940900 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2311 - Andrew E. Mathis, 2009 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2312 - Cousins 2010 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2313 - Helzner 2007 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2314 - FDA, Guidance for Industry, 2014 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2315 - NCT01486771 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2316 - Gallemore 2008 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2317 - Press Release, Kanghong Pharmaceutical | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2318 - Kanghong Press Release - Chinese | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2319 - Thomas 2013 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2320 - Ohr 2012 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2321 - FDA Approves Eylea for Wet AMD | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2322 - AAO_What is a Slit Lamp_ - American_Bate-Stamped | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2323 - Albini, Thomas 032123 Full Size | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2324 - Gerritsen Depo Transcript | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2325 - Gerritsen, Mary 031723 Transcript | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2326 - Albini Depo Ex 14 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2327 - 2023-01-06 [02] Petition for IPR of 681 Patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2328 - MYL_News_2018_1_3_General_Releases | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2329 - [CONFIDENTIAL] Colyer Declaration 601 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2329 - [REDACTED] Colyer Declaration 601 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2330 - Ex. 1002 - Albini Decl (681) - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2330 - Ex. 1002 - Albini Decl (681) - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2331 - 338 FH - Part 1 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2331 - 338 FH - Part 2 of 2 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2332 - Ophthotech Press Release | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2333 - Genentech Press Release | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2334 - Ciulla & Rosenfeld - Anti-vascular endothelial growth factor therapy | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2335 - 069 Patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2336 - 757 Patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2337 - 959 Patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2338 - Gerritsen Reply Decl. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2339 - Gerritsen Decl -880 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2340 - Gerritsen Reply Decl. 069 patent | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2341 - Albini Reply Decl. | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2342 - [CONFIDENTIAL] Ivan Hofmann Depo Tr. -881 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2342 PUBLIC - Ivan Hofmann Depo Tr. -881 - Part 1 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2342 PUBLIC - Ivan Hofmann Depo Tr. -881 - Part 2 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2342 PUBLIC - Ivan Hofmann Depo Tr. -881 - Part 3 of 3 | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Ex. 2344 - 191459_1639726707-12-2022DIST (1) | Apr 5, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Unopposed Motion for Entry of Default Protective Order | Apr 3, 2023 | PAPER | PATENT OWNER |
Patent Owner's Second Objections to Evidence | Apr 3, 2023 | PAPER | PATENT OWNER |
Order: Conduct of the Proceeding | Mar 28, 2023 | PAPER | BOARD |
Institution decision and grant of joinder, IPR2023-00533 | Mar 22, 2023 | PAPER | BOARD |
Institution decision and grant of joinder, IPR2023-00566 | Mar 22, 2023 | PAPER | BOARD |
ORDER Granting Patent Owner’s Motion for Admission pro hac vice of Abigail Struthers, Daniel L. Reisner, Jeremy Cobb, Victoria Reines, and Matthew M. Wilk | Mar 1, 2023 | PAPER | BOARD |
Patent Owner's Notice of Deposition of Dr. Thomas A. Albini | Mar 1, 2023 | PAPER | PATENT OWNER |
Patent Owner's Notice of Deposition of Mary E. Gerritsen, Ph.D. | Mar 1, 2023 | PAPER | PATENT OWNER |
SCHEDULING ORDER | Feb 8, 2023 | PAPER | BOARD |
Patent Owner's Pro Hac Vice Motion to Admit Abigail Struthers | Feb 6, 2023 | PAPER | PATENT OWNER |
Ex. 2050 - Declaration of Abigail Struthers | Feb 6, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Pro Hac Vice Motion to Admit Daniel Reisner | Feb 6, 2023 | PAPER | PATENT OWNER |
Ex. 2051 - Declaration of Daniel Reisner | Feb 6, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Pro Hac Vice Motion to Admit Jeremy Cobb | Feb 6, 2023 | PAPER | PATENT OWNER |
Ex. 2052 - Declaration of Jeremy Cobb | Feb 6, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Pro Hac Vice Motion to Admit Victoria Reines | Feb 6, 2023 | PAPER | PATENT OWNER |
Ex. 2053 - Declaration of Victoria Reines | Feb 6, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Pro Hac Vice Motion to Admit Matthew Wilk | Feb 6, 2023 | PAPER | PATENT OWNER |
Ex. 2054 - Declaration of Matthew Wilk | Feb 6, 2023 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Exhibit List | Feb 6, 2023 | PAPER | PATENT OWNER |
Patent Owner's Power of Attorney | Feb 2, 2023 | PAPER | PATENT OWNER |
Patent Owner's Amended Mandatory Notices | Feb 2, 2023 | PAPER | PATENT OWNER |
Petitioner's Updated Mandatory Notice | Jan 27, 2023 | PAPER | PETITIONER |
Petitioner's Objections to Patent Owner's Exhibits | Jan 26, 2023 | PAPER | PETITIONER |
Patent Owner's Objections to Petitioner's Exhibits | Jan 20, 2023 | PAPER | PATENT OWNER |
Institution Decision: Grant | Jan 11, 2023 | PAPER | BOARD |
Ex. 3001 | Jan 11, 2023 | EXHIBIT | BOARD |
Petitioner's Amended Mandatory Notices | Dec 29, 2022 | PAPER | PETITIONER |
Patent Owner's Sur-Reply to Petitioner's Reply to POPR | Nov 14, 2022 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | Nov 14, 2022 | PAPER | PATENT OWNER |
Ex. 2045 - Email from N. McLauglin to D. Fishman et al | Nov 14, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2046 - Stipulation, DN 88 in N.D.W. Va | Nov 14, 2022 | EXHIBIT | PATENT OWNER |
Reply to POPR | Nov 7, 2022 | PAPER | PETITIONER |
Petitioner's Updated Exhibit List | Nov 7, 2022 | PAPER | PETITIONER |
Ex.1101 - Transcript | Nov 7, 2022 | EXHIBIT | PETITIONER |
Ex.1103 - Scheduling Order | Nov 7, 2022 | EXHIBIT | PETITIONER |
ORDER Granting Petitioners Motion for Admission Pro Hac Vice of Lauren M. Lesko 37 C.F.R. sec 42.10 | Nov 4, 2022 | PAPER | BOARD |
L. Lesko Motion for PHV Admission | Oct 24, 2022 | PAPER | PETITIONER |
Ex. 1100 - Lesko Decl. | Oct 24, 2022 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List | Oct 24, 2022 | PAPER | PETITIONER |
Preliminary Response of Patent Owner | Oct 13, 2022 | PAPER | PATENT OWNER |
Ex. 2003 - US Patent 10,130,681 B2 | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2004 - Third Party Submission in '345 File History | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2005 - Notice of Acceptance of Third Party Submission from '345 File History | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2006 - Office Action from '345 File History | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2007 - Declaration of Rachel Watters | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2008 - Complaint, DI 1 from N.D.W. Va. | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2009 - Response to motion, DI 26 from N.D.W. Va. | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2010 - District Court Statistics | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2011 - Motion for expedited status conference, DI 7 from N.D.W. Va. | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2012 - Answer, DI 47 from N.D.W. Va. | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2013 - Joint report of planning meeting , DI 75 from N.D.W. Va. | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2014 - US Patent 7,303,748 | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2015 - US Patent 7,070,959 | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2016 - US Publication 2006_0172944 A1 | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2017 - US Publication 2005_0163798 A1 | Oct 13, 2022 | EXHIBIT | PATENT OWNER |
E. Hunt Motion for PHV Admission | Sep 29, 2022 | PAPER | PETITIONER |
Declaration in Support of E. Hunt PHV Admission | Sep 29, 2022 | EXHIBIT | PETITIONER |
H. Salmen Motion for PHV Admission | Sep 29, 2022 | PAPER | PETITIONER |
Declaration in Support of H. Salmen PHV Admission | Sep 29, 2022 | EXHIBIT | PETITIONER |
W. Rakoczy Motion for PHV Admission | Sep 29, 2022 | PAPER | PETITIONER |
Ex. 1097 - Declaration in Support of W. Rakoczy PHV Admission | Sep 29, 2022 | EXHIBIT | PETITIONER |
Updated Mylan Power of Attorney | Sep 29, 2022 | PAPER | PETITIONER |
Petitioner's Amended Mandatory Notices | Sep 29, 2022 | PAPER | PETITIONER |
Petitioner's Updated Exhibit List | Sep 29, 2022 | PAPER | PETITIONER |
Petitioner's Amended Mandatory Notices | Aug 23, 2022 | PAPER | PETITIONER |
Patent Owner's Power of Attorney | Aug 8, 2022 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | Aug 8, 2022 | PAPER | PATENT OWNER |
Notice: Notice filing date accorded | Jul 13, 2022 | PAPER | BOARD |
Ex 1001 - '601 patent | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1004 - Holash | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1005 - Nguyen-2009 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1006 - Dixon | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1007 - Adis | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1008 - '173 patent | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1009 - '664 patent | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1010 - '758 patent | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1011 - Semeraro | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1012 - Regeneron (28-April-2008) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1013 - Regeneron (8-May-2008) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1014 - NCT-795 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1015 - NCT-377 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1016 - IPR2021-00881 Ex.1109 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1018 - Heier-2012 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1019 - IPR2021-00881 Ex. 2051 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1020 - Heier-2009 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1021 - 2009 10-Q | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1022 - IPR2021-00881 Ex.1110 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1023 - '959 FH, 12-22-2011 PTE | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1024 - '758 FH, 12-22-2011 PTE | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1025 - Engelbert-2010 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1026 - Rudge-2007 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1027 - Spaide | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1028 - IPR2021-00881 Ex. 2080 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1029 - Gomez-Manzano | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1030 - Mitchell | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1031 - Quiram | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1032 - Bayer (8-May-2008) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1033 - Dix | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1034 - Fung | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1035 - Lalwani | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1036 - Fraser | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1037 - Lucentis MR | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1038 - Albini CV | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1039 - '095 patent | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1040 - Heimann-2007 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1041 - Regeneron (26-February-2009) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1042 - NIH AMD | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1043 - Brown | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1044 - NIH DR | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1045 - Ferrara-1999 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1046 - Ferrara-2005 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1047 - Bashshur | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1048 - Lucentis | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1049 - Spielberg | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1050 - Eylea MR | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1051 - Keane | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1052 - Rudge | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1053 - Regeneron (27-March-2007) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1054 - Regeneron (2-August-2007) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1055 - Retina Society Meeting Presentation | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1056 - Regeneron (28-September-2008) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1057 - Jager-2004 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1058 - Rosenfeld-2006 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1059 - Christensen | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1060 - Mueller | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1061 - Gerritsen CV | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1062 - EP-325 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1063 - EP-325-FH | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1064 - Wayback-BJO-Online First | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1065 - BJO-Article Metrics | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1066 - EP-285 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1067 - EP-285-FH | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1068 - Regeneron (14-September-2009) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1069 - Background-ClinicalTrials.gov | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1070 - Wayback-Affidavit | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1071 - '338 patent | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1072 - Reichert | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1073 - Anderson | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1074 - Ciulla | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1075 - Ni | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1076 - Zarbin | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1077 - Corporate Finance Institute | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1078 - Schneider | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1079 - Kuepper | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1080 - Zucchi | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1081 - Hayes | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1082 - Wilhelmus-1988 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1083 - Wirbelauer-2006 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1084 - IPR2021-00881 Ex. 2055 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1085 - IPR2021-00881 Ex. 2050 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1086 - IPR2021-00881 Ex. 2098 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1087 - AA Alignment vs 758 and 959 patents | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1088 - Nguyen-2006 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1089 - Regeneron (19-August-2008) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1090 - IPR2021-00881 Ex. 2103 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1091 - Rudge-2008 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1092 - AA Alignment vs 758 and 173 patents | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1093 - NA Alignment vs 758 and 173 patents | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1094 - History-ClinicalTrials.gov | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1095 - Wayback-Affidavit-601 | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1096 - '681 FH | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1017 - '601 FH (1 of 5) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1017 - '601 FH (2 of 5) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1017 - '601 FH (3 of 5) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1017 - '601 FH (4 of 5) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1017 - '601 FH (5 of 5) | Jul 1, 2022 | EXHIBIT | PETITIONER |
Power of Attorney | Jul 1, 2022 | PAPER | PETITIONER |
Ex 1003 - Gerritsen | Jul 1, 2022 | EXHIBIT | PETITIONER |
Ex 1002 - Albini | Jul 1, 2022 | EXHIBIT | PETITIONER |
Petition | Jul 1, 2022 | PAPER | PETITIONER |